| 1 | Acupoint application therapies for essential hypertension:a systematic review and Meta-analysis显示文摘OBJECTIVE:To evaluate the efficacy and safety of acupoint application therapies(AA)for hypertension.METHODS:We searched Pub Med,EMBASE,the Cochrane Center Controlled Trials Register,Chinese National Knowledge Infrastructure,Chinese Scientific Journal Database,and Wanfang Med Online Database from their inceptions to October 7,2019.No language restriction was applied.We included randomized clinical trials testing AA against Western Medicine,AA versus placebo,AA combined with Western Medicine versus Western Medicine.Study selection,data extraction,quality assessment,and data analyses were conducted according to the Cochrane standards.RESULTS:Totally 41 trials with 3772 participants were included.The methodological quality of the included trials was evaluated as generally low.AA plus Western Medicine significantly lowered systolic blood pressure(BP)[weighted mean difference(WMD):-10.36,95%confidence intervals(CI):-12.62,-8.10;P<0.00001],diastolic BP(WMD:-5.71,95%CI:-7.30,-4.13;P<0.00001),and total effect[risk ratio(RR):1.23,95%CI:1.15,1.32;P<0.00001].The BP-lowering effect of AA was significantly higher than that of placebo[systolic BP(SBP):-8.05,95%CI:-8.67,-7.43;P<0.00001;diastolic BP(DBP):-6.66,95%CI:-7.31,-6.01,P<0.00001].The total effect also improved significantly from baseline with AA than placebo(RR:10.85,95%CI:4.71,24.98;P<0.00001).Traditional Chinese Medicine symptoms score were significantly reduced by AA compared with Western Medicine(WMD:-1.75,95%CI:-2.52,-0.99;P<0.00001),10 trials reported adverse events,indicating that the safety of SSYX Capsule is still uncertain.CONCLUSIONS:Application therapies may be considered a safe and beneficial for the treatment of hypertension and can reduce BP and improve the total effect.Further well-designed trials are needed to support our conclusions. | LIU Wei XIONG Xingjiang QIAO Lumin CHEN Yuyi LI Yixuan SU Xing CHU Fuyong LIU Hongxu | 2022 | Journal of Traditional Chinese Medicine2022，42，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员